Lamotrigine (All indications)

Study	Exclusion reasons	Rmk	Reference
Christensen (Lamotrigine) (Indications NOS), 2019		Indications not specified. Overlapping: For ADHD: Christensen 2019 totally included in a larger study published by Dreier 2023 (longer study period and 5 countries) => use of Dreier 2023 data	Christensen JAMA Netw Open 2019; 2:e186606 10.1001/jamanetworkopen.2018.6606
Daugaard (Lamotrigine) (Indications NOS), 2020		Indications not specified. Overlapping between Bjork 2022 and Daugaard 2020 for Intellectual disabilities (2 outcomes), with more pregnancies in Bjork 2022 because longer study period and 5 countries => use of Bjork 2022 data.	Daugaard JAMA Netw Open 2020; 3:e2025570 10.1001/jamanetworkopen.2020.25570
Husebye (Lamotrigine) (Controls unexposed, disease free), 2018		EXCLUDED: completely overlapped by Husebye et al. 2020 (same cohort, older children for neurodevelopmental outcomes). For those groups, results are only available according to folic acid intake.	Husebye Neurology 2018; 91:e811-e821 10.1212/WNL.0000000000006073
Husebye (Lamotrigine) (Controls unexposed, sick), 2018		EXCLUDED: completely overlapped by Husebye et al. 2020 (same cohort, older children for neurodevelopmental outcomes). For those groups, results are only available according to folic acid intake.	Husebye Neurology 2018; 91:e811-e821 10.1212/WNL.0000000000006073
Coste (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2020		EXCLUDED: this control group doesn't exist in the article (only in the report). Children with a diagnosis of brain malformation (ICD-10 codes Q00 to Q04 and Q05.0 to Q05.4) during their stay in the maternity unit are excluded.	Coste Sci Rep 2020; 10:17362 10.1038/s41598-020-74409-x
He (Lamotrigine), 2017	repeat population groups, duplicate reports (most recent study included)	Patients who developed epilepsy during pregnancy or after delivery were not included. Overlapping: He 2017 totally included in Li 2023, with a longer study period and more pregnancies => Use of Li 2023.	He Epilepsy Behav 2017; 74:10-14 10.1016/j.yebeh.2017.05.034
Elkjaer (Lamotrigine) (Mixed indications), 2018	repeat population groups, duplicate reports (most recent study included)	Overlapping: this publication totally included the data of Elkjaer, 2018, for an higher academic grade => use of Ren 2023.	Elkjaer JAMA Neurol 2018; 75:663-671 10.1001/jamaneurol.2017.5035
Meador, 2021	repeat population groups, duplicate reports (most recent study included)	Imputations analysis reported here. Overlapping: Meador 2021 and 2023 used the same cohort in order to study the same outcome, at 2 different ages (=> use of the data on the older children, i.e Meador 2023).	Meador JAMA Neurol 2021; 78:927-936 10.1001/jamaneurol.2021.1583